VisiJet Acquires Worldwide Distribution Rights of Gebauer Products and Receives $9.5 Million Financing Commitment.

Business Editors/Health/Medical Writers

IRVINE, Calif.--(BUSINESS WIRE)--May 10, 2004

VisiJet, Inc. (OTCBB:VJET), developers of innovative technologies for the ophthalmic surgical market, announced it has acquired the exclusive worldwide distribution, sales and marketing rights for the LASIK and Epi-Lasik products from Gebauer Medizintechnik GmbH of Neuhausen, Germany. Starboard Capital Markets LLC, a registered broker dealer based in Philadelphia, assisted the company in the financing of the acquisition. In addition, SBI Brightline II, LLC an affiliate of SBI USA, LLC, and Trilogy Investment have increased their original financing commitment of $4.5 million by $5 million to provide $9.5 million in capital for product development and working capital. The funding is subject to certain contingencies, including the effectiveness of a Registration Statement with the Securities and Exchange Commission.

"The acquisition of the distribution rights for the products -- the LasiTome and the Epi-Tome -- complements our ophthalmic surgical products under development and provides immediate revenue opportunities for the Company," said Randy Bailey, CEO and President of VisiJet. "Gebauer, a known international innovator, has improved upon existing technologies and developed these ground-breaking microkeratomes with unique cutting and separating methods that should eliminate many postoperative problems. With the Epi-Tome, LasiTome, and HydroKeratome approved and launched, VisiJet will be the only company able to offer the surgeon the option of preparing the cornea for both surface ablation or stroma ablation."

The Epi-Tome is currently CE marked (EU equivalent to FDA approval) and already being sold in Europe and other countries accepting that designation. The Company anticipates filing for FDA approval within the next few weeks. The Epi-Tome and LasiTome join a growing refractive surgery market estimated in excess of $4 billion annually worldwide.

Dr. Ronald Krueger, MD, MS, Medical Director of Refractive Surgery, Cole Eye Institute, The Cleveland Clinic Foundation, anticipates superior results with the Gebauer Epi-Tome as it maintains the structure of the cornea.

"The blade of the Epi-Tome is designed to 'ride' on the Bowman's plane, directing the cutting force upwards, away from the stroma," explained Dr. Krueger. "The resulting flap is smooth, intact and easily repositioned on the eye. Also the blade is steel, not plastic, and its sharper edge produces a clean more precise and accurate separation of tissue." Dr. Krueger believes because the Epi-Tome keeps the stroma intact and the technique does not require alcohol, problems such as postoperative pain, and dry eye will be eliminated or greatly reduced.

"The Epi-Tome is an advance in LASIK with important advantages for both patient and surgeon," stated Dr. Krueger. "I believe it will have a prominent place in refractive surgery."

ABOUT VISIJET, INC.

VisiJet, Inc. is a medical device company based in Irvine, California focused on the development and marketing of innovative ophthalmic applications that will result in faster, safer and more efficacious procedures in two of the largest surgical markets in the world: refractive and cataract surgeries. VisiJet's lead products, the HydroKeratome(R) and Pulsatome(R), utilize the Company's proprietary and patented waterjet technology that uses a high-pressure micro beam of water the diameter of a human hair to cut ocular tissue. The FDA-approved HydroKeratome(R), uses the waterjet technology to cut the cornea as required in LASIK surgery. The Pulsatome(R), currently under development, is a device that uses waterjet technology to remove cataracts - the most performed surgical procedure in the world. VisiJet, Inc. is located at 192 Technology Drive, Suite Q, Irvine, CA. PH: 949-450-1660, FX: 949-453-9652, Investor Relations: 949-450-1660 ext. 26. Website: www.visijet.com

FORWARD-LOOKING STATEMENTS

Except for historical information contained herein, the matters discussed in this news release are forward-looking statements within the meaning of the Securities Exchange Act that involve risks and uncertainties that could cause actual results to differ materially from those expressed. These matters include, but are not limited to, the anticipated financing information about the Company's technologies and products, financial situations, or business opportunities. This news release shall not constitute an offer to sell or the solicitation of an offer to sell any of these securities.